RE: Canine cancer efficacy 88% An incredibly high efficacy rate for Immunocidin. As an "indirect" comparative I have quickly "copied & pasted" info from a previous May 5-12 post. But first, two sentences from Beech's post last night re....
"ImmunocidinTM is an improved form of RegressinTM and the regulators accepted the same licensing data in support of its registration. The study found that 88% of dogs treated with M. phlei compounds as the sole treatment for mammary cancer were tumor-free two years later."
Now, let's compare Immunocidin's 88% tumour-free (2 years later) efficacy rate with the other Canine Cancer treatment in the market (Pfizer's Palladia). The following are excerpts from an article (link below) but keep in mind Palladia is for a different type of cancer (treatment for mast cell tumours in dogs).
Hope for Curing Canine Cancer (article):
The drug works by blocking the activity of key receptors important for the development of blood vessels that supply tumors, as well as receptors critical for tumor survival.
"At the completion of a Palladia clinical study, approximately 60 percent of the dogs had their tumors disappear, shrink or stop growing," said Cheryl London, DVM, PhD, board-certified medical oncologist and associate professor at The Ohio State University College of Veterinary Medicine. "Also, we determined that dogs whose tumors responded to Palladia experienced an improved quality of life." Dr. London has worked with Pfizer Animal Health's Veterinary Medicine Research & Development in developing Palladia since 2000.
https://www.petspress.net/articles/2009/july2009/caninecancer.html
Now, let's dig a little deeper into the above "60 percent" statistic using the following document:
Freedom of information summary - Original new animal drug application - NADA 141-295 - PALLADIA - toceranib phosphate tablets - dogs
https://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM164091.pdf
Here are Palladia's clinical trial results (FDA info):
Complete Response (CR): 8.1%
Partial Response (PR): 29.1%
Stable Disease (SD): 20.9% Thus, CR + PR + SD = 58.1% --> 60%
Progressive Disease (PD): 32.6%
D/C for Adverse Event: 3.5%
D/C due to owner's request 5.8%
Total: 100%
Number of dogs: 86. Study length: 6 week results (but over a two year period to achieve)....I believe
So, Pfizer takes a base CR statistic of 8.1% and embellishes it (adds to it) with PR and SD statistics then rounds up to 60% and "front and centres" this combo/upsized statistic. Meanwhile, Immunocidin has an 88% CR rate statistic which who knows about? (please correct me if I am using CR inappropriately). A very powerful benefit and competitive advantage! Alongside with Immunocidin's safety and costs advantages which were mentioned in Bioniche's press release.
Also, Immunocidin's 88% efficacy rate reflects very well for Bioniche's MCC technology platform (albeit, indirectly). And, from that platform not only comes Urocidin, well into the second Phase 3 trial which is being fully funded by Endo...but hopefully, other cancer treatments in the foreseeable future, possibly with other potential partners that should be hearing all this now.
BTW...saw a news article on the launch of Immunocidin this morn (from Australia) which I thought was quite well written using Bioniche's press release info . See link below. rg
https://www.lifescientist.com.au/article/439573/bioniche_launches_canine_cancer_product_na/